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Abstract  
Introduction: This study examines and compares the dosimetric quality 
of radiotherapy treatment plans for prostate carcinoma across a cohort of 
163 patients treated across 5 centres: 83 treated with three-dimensional 
conformal radiotherapy (3DCRT), 33 treated with intensity-modulated 
radiotherapy (IMRT) and 47 treated with volumetric-modulated arc 
therapy (VMAT). 
Methods: Treatment plan quality was evaluated in terms of target dose 
homogeneity and organ-at-risk sparing, through the use of a set of dose 
metrics. These included the mean, maximum and minimum doses; the 
homogeneity and conformity indices for the target volumes; and a 
selection of dose coverage values that were relevant to each organ-at-
risk. Statistical significance was evaluated using two-tailed Welch’s T-
tests. The Monte Carlo DICOM ToolKit software was adapted to permit the 
evaluation of dose metrics from DICOM data exported from a commercial 
radiotherapy treatment planning system. 
Results: The 3DCRT treatment plans offered greater planning target 
volume dose homogeneity than the other two treatment modalities. The 
IMRT and VMAT plans offered greater dose reduction in the organs-at-
risk: with increased compliance with recommended organ-at-risk dose 
constraints, compared to conventional 3DCRT treatments. When 
compared to each other, IMRT and VMAT did not provide significantly 
different treatment plan quality for like-sized tumour volumes. 
Conclusions: This study indicates that IMRT and VMAT have provided 
similar dosimetric quality, which is superior to the dosimetric quality 
achieved with 3DCRT. 
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Introduction: 
Because the prostate is surrounded by radiosensitive organs and load-
bearing bones, there is growing interest in delivering radiotherapy 
treatments to prostate carcinomas using inverse-planned intensity-
modulated radiotherapy (IMRT)1 and volumetric-modulated arc therapy 
(VMAT),2 which are expected to provide improved organ-at-risk dose 
sparing compared to conventional three-dimensional conformal 
radiotherapy (3DCRT) treatments. Given that there are differences in 
treatment planning and delivery efficiency between IMRT, VMAT and 
3DCRT,2,3,4 it is important to examine the dosimetric quality achieved with 
intensity-modulated techniques, and review any differences observed 
between the modalities.  
 
Reports of the improved organ-at-risk sparing achievable with IMRT have 
often been based on prospective studies, where IMRT and 3DCRT 
treatments are planned for small numbers of patients and the resulting 
dose distributions are compared.5,6,7,8,9 A study by Zelefsky et al.5 
reported that IMRT allowed reduced rectal and bladder doses and 
improved coverage compared to 3DCRT in a study of 20 concomitantly 
planned treatments. Luxton et al.6 found that accurately delivered IMRT 
for prostate cancer can limit dose to normal tissue. Hardcastle et al.9 
found IMRT allowed rectal dose reductions.  
 
Similarly, reports of the improved dose distributions achievable with VMAT 
have largely relied upon prospective comparisons against IMRT using a 
small numbers of treatment plans, and have produced some contradictory 
results.4,10,11,12,13 For example, Yoo et al.4 found that conventional IMRT 
performed better than RapidArc (the VMAT implementation of Varian 
Medical Systems, Palo Alto, USA) in bladder, rectum and small bowel dose 
sparing while obtaining comparable coverage of the planning target 
volume (PTV) in a study using data from 10 patients. By contrast, Kjær-
Kristofferson et al.10 found that the RapidArc optimisation algorithm 
provided better or equal sparing of organs at risk compared to IMRT 
plans, with decreased target dose homogeneity, in a study of 8 prostate 
cancer patients. Jacob et al.11 found RapidArc achieved greater rectum 
and bladder dose sparing while achieving similar PTV dose homogeneity 
as dynamic IMRT and helical tomotherapy in a study of 9 patients. 
Similarly, Hardcastle et al.’s12 10-patient study found that a VMAT 
technique provided improved rectal dose sparing compared to standard 
IMRT. Sze et al.13 found that RapidArc could provide greater dosimetric 
quality than IMRT in a study of 14 patients. 
 
Two studies have compared 3DCRT with IMRT and VMAT. Wolff et al.8 
found that IMRT, VMAT and serial tomotherapy offered improved quality 
plans for a set of 9 patients. A study by Palma et al.7 compared 
achievable dose distributions for 3DCRT, IMRT and VMAT techniques over 
10 patient CT datasets, finding that IMRT and VMAT treatments offered 
greater dose reduction in critical organs, and that a variable dose rate 
VMAT technique provided the greatest dosimetric quality. 
 
A small number of retrospective examinations of delivered VMAT plans 
have been reported.3,14 Pesce et al.14 examined treatment plans for 45 
prostate cases and found that VMAT prostate treatments were meeting 
improved clinical objectives, but did not compare calculated dose metrics 
with those of other treatment modalities. Aznar et al.3 found that VMAT 
resulted in a significantly lower dose to the rectum at the expense of PTV 
coverage in a mean-DVH comparison between 46 VMAT treatment plans 
and 50 independent IMRT plans. 
 
While prospective treatment plan quality studies are more numerous, in 
the literature, than retrospective plan quality studies, there are important 
advantages to investigating data from both prospective and retrospective 
studies. Retrospective analyses of treatments delivered to patients 
provide valuable examples of the clinical application of different treatment 
modalities.  
 
This study retrospectively examines a large number of prostate 
treatments planned and delivered using 3DCRT, IMRT and VMAT, in terms 
of an extended list of dose metrics, in order to provide a detailed and 
robust illustration of the plan quality that may be achieved, clinically, 
using these modalities. The number of patients involved is greater, by an 
order of magnitude than any cohort examined in previously published 
prospective or retrospective plan quality studies, and the set of dose 
metrics evaluated is more comprehensive than any previously applied. 
This analysis allows objective assessment of the quality of the plans and 
thereby provides an indication of the advantages and limitations of the 
3DCRT, IMRT and VMAT radiotherapy techniques as used at the centres 
involved in this study.  
 
Methods: 
Patient Plans: 
The treatments were planned on the Eclipse treatment planning system 
(Varian Medical Systems, Palo Alto, USA) version 8.6, using the 
Anisotropic Analytical Algorithm (AAA) dose calculation engine. The 
patient group received prostate cancer treatments contemporaneously 
planned and delivered over a 2 year period (January 2010 through 
February 2012), on 7 dosimetrically matched linear accelerators located 
at 5 centres operated by Premion. The QUT University Human Research 
Ethics Committee assessed this research as meeting the conditions for 
exemption from HREC review and approval in accordance with section 
5.1.22 of the National Statement on Ethical Conduct in Human Research 
(2007).15 
 
A total of 163 treatment plans were selected for analysis: 83 treated with 
3DCRT, 33 treated with IMRT and 47 treated with VMAT (specifically 
RapidArc). A further 71 plans were excluded due to deviations from the 
standard planning process. Plans were excluded when the treatment 
intent was not curative or radical; brachytherapy had been used in 
conjunction with external beam therapy; altered beam arrangements had 
been used, for example, where the treatment was altered due to machine 
servicing or failures; and where there were significant artefacts in the CT 
data due to hip prostheses. Treatments of prostate beds were included.  
 
Variations in Gleason score and clinical target volume (CTV, measured in 
cc) were evaluated using a series of two-tailed Welch’s T-tests to 
establish whether there was significant variation between the 3 treatment 
modality cohorts. 
 
The 3DCRT treatments typically contained 6 beams: a lateral opposed 
pair (90° and 270°), an anterior oblique pair (30° and 330°) and a 
posterior oblique pair (125-135° and 225-235°); frequently with wedges 
to compensate for the patient anatomy. The most common prescription 
was 70 Gy to the intact prostate (45% of patients). Alternative 
prescriptions for treatments of the prostate bed following a radical 
prostatectomy were 64 Gy for adjuvant RT (38% of patients) and 66 Gy 
for salvage RT (15% of patients). 
 
The IMRT treatments generally contained either 5 or 7 beams: an anterior 
beam (0°), an anterior oblique pair (45° and 315°) and a posterior 
oblique pair (100° and 260°). The PTV dose prescriptions were 78 Gy for 
intact prostates and 66 Gy (1 patient) for treatments of the prostate bed. 
 
The majority of the VMAT treatments utilized 2 360° arcs, rotating in 
opposite directions.  The prescription for intact prostates was generally 78 
Gy, with prescriptions of 66 Gy (1 patient), 70 Gy (3 patients) and 74 Gy 
(15 patients) delivered to prostate beds.  
 
Prescriptions were defined in terms of the dose to an ICRU prescription 
point,16 with a minimum coverage dose of 95% and a maximum accepted 
hotspot dose of 107%. Where a volumetric prescription was specified the 
prescription was scaled accordingly. The prescription doses were therefore 
approximately equal to the PTV median dose values. 
 
The PTVs were defined using a 10mm expansion to the CTVs, without 
scalloping around the rectum. The rectal volume was contoured from the 
inferior end of the sigmoid colon, down to the superior end of the anus, at 
the pelvic floor. For inverse planning (that is, for IMRT and VMAT) the 
rectal volume minus the PTV volume was used for dose optimisation. Data 
presented here are for the whole rectal volume. Patients were imaged 
with full bladders and empty rectums. 
 
All treatment plans examined in this study were contemporaneously 
devised by trained planning staff who were unaware that their work would 
be used in any subsequent retrospective analysis. Each modality was 
utilised over the whole 2 year period. Patient selection for each modality 
was determined by the availability of the different modalities at each 
centre (VMAT was available at 2 centres, IMRT at another 2 centres). 
 
Dose Metrics: 
Treatment plan data was exported from the Eclipse treatment planning 
system using the DICOM export functionality, producing an RTPLAN file 
(containing beam parameters), an RTSTRUCT file (containing volume 
definitions) and an RTDOSE file (containing the calculated dose 
distribution). The dose assessment metrics were extracted with TADA 
(Treatment and Dose Assessor), an expansion to the MCDTK (Monte Carlo 
DICOM ToolKit) software suite.17,18 
 
The TADA software utilizes the mDCM DICOM library to parse the 
information stored in the DICOM files. The calculated dose values in each 
of the volumes of interest were selected by scanning through the RTDOSE 
distribution, recording values contained in the structure. Determining 
whether a voxel dose value should be included in the volume population 
was done using a ray-casting point-in-polygon algorithm;19 where the 
polygons were defined as the contours resulting from CT-slice 
segmentation (as stored in the RTSTRUCT files).  
 
The TADA processing of the DICOM data produced text files for each 
patient, presenting the dose metrics for each volume defined for the 
patient CT dataset, the dose metrics for that volume, the conformity 
indices for the plan and a report on whether dose objectives had been 
met. 
 
The dose metrics exported in these files were selected on a per-structure 
basis: for treatment volumes the minimum, near-minimum (D98%), 
median, near-maximum (D2%) and maximum doses were included; for 
organ-at-risk volumes clinically relevant metrics were also included.  
 
Two organ-at-risk guidelines were adopted from objectives presented by 
Marks et al.20 and Michalski et al.21 as part of the QUANTEC analysis of 
normal tissue effects: that no more than 35% of the rectum should 
receive 60 Gy (V60Gy≤35%) and no more than 20% of the rectum should 
receive 70 Gy (V70Gy≤20%). The 40 Gy rectal coverage was also 
evaluated, to provide an additional comparison point, which corresponded 
to Hansen and Roach’s22 sample dose constraint, that no more than 50% 
of the rectum should receive 40 Gy (V40Gy≤50%). Dose to the femoral 
heads was evaluated in terms of the recommendation in Lawton et al.’s23 
RTOG prostate radiotherapy trial consensus report that no more than 5% 
of the femoral heads should receive 50 Gy (V50Gy≤5%). For each 
treatment modality, the percentage of plans meeting these 
recommendations was evaluated, as was the mean coverage dose at each 
of the relevant dose levels. 
 PTV dose values were averaged over all patients treated with each 
treatment modality, after being normalized against the patient's ICRU 
prescription point dose. Individual organ-at-risk dose values were 
normalized against the patient’s median PTV doses before averaging. 
These normalisations allowed the organ-at-risk dose sparing provided by 
the treatments to be compared despite the differences in the PTV 
prescriptions. A comparison without this normalisation of organ-at-risk 
dose was performed for IMRT and VMAT treatments with 78 Gy PTV 
coverage prescriptions. 
 
A homogeneity index (HI) was used to evaluate the heterogeneity of dose 
to the treatment volumes, which was defined as:16 
𝐻𝐼 =
𝐷2% − 𝐷98%
𝐷50%
 
where a result approaching zero indicates that the absorbed dose 
distribution is near-homogeneous.  
 
The equivalent uniform doses (EUDs)24,25 in the prostate and femoral 
heads were calculated as 
𝐸𝑈𝐷 = (∑𝑣𝑖 × 𝐷𝑖
1
𝑛
𝑖
)
𝑛
 
where vi is the partial volume receiving dose Di, and n describes the 
volumetric dependence of the dose-response relationship. The n values 
used in this study were taken from Burman et al.:26 0.12 for the rectum 
and 0.25 for the femoral heads. 
 
Two different conformity indices were calculated: the RTOG conformity 
index (CI),27 a ratio of the volume of the reference isodose and the target 
volume; and the van't Riet conformation number (CN),28 which takes into 
account both target volume and healthy tissue irradiation.29 The CN was 
defined as: 
𝐶𝑁 =
𝑇𝑉𝑅𝐼
𝑇𝑉
×
𝑇𝑉𝑅𝐼
𝑉
 
where TV is the target volume, TVRI is the target volume covered by the 
reference isodose and VRI is the volume of the reference isodose. For both 
CI and CN a value approaching 1 indicates high conformity. 
 
Mean HIs, EUDs, CIs and CNs were calculated for each group of patients 
treated with each radiotherapy modality. The large dataset used in this 
study allow calculated metrics to be stratified in terms of target size. 
Small CTVs were defined as being less than 50 cc, medium being 50 to 70 
cc, and large being greater than 70 cc. 
 
Confidence limits were evaluated as the standard deviation from each 
mean. The significance of the statistical variations between the three 
groups were expressed as p-values calculated using two-tailed Welch's T-
tests for each modality pair (3DCRT vs. IMRT, 3DCRT vs. VMAT and IMRT 
vs. VMAT). Smaller P-values suggest that the differences between the 
datasets are unlikely to have arisen by random fluctuations. 
 
Results:  
The results of the dose assessments across the entire cohort are 
presented in Tables 1 and 2. Table 3 presents results stratified according 
to CTV size.  
 
There was no significant difference between the Gleason scores and 
clinical target volumes for the 3DCRT, IMRT and VMAT cohorts (p>0.05 in 
most cases). These results suggest that there was no significant 
difference between the pathologies treated using the 3 radiotherapy 
modalities. The higher mean clinical target volume seen with 3DCRT is 
due to a difference in the proportion of prostate bed treatments.  
 
There was a significant difference between the prescription doses and the 
number of monitor units (p<0.001) required to deliver these doses across 
the 3 modalities. The differences in monitor unit efficiency (the number of 
MU required to delivery 1 Gy of prescription dose) was statistically 
significant (p<0.001). The VMAT treatments, on average, required the 
delivery of fewer monitor units, requiring less treatment-delivery time, 
than IMRT, but both modalities required significantly more monitor units 
than 3DCRT. 
 
Data in Tables 1 and 3 show that the median PTV and prescription dose 
ratios for the 3DCRT, IMRT and VMAT treatments were near unity and not 
significantly different. The differences in the other PTV dose metrics were 
significant: the IMRT and VMAT treatments showed higher maximum and 
near-maximum doses (p<0.05 in all cases), and generally greater 
heterogeneity (p<0.001 and p=0.002 for medium CTVs respectively). 
 
Data in Tables 1 and 2 also indicate that the dose sparing of the rectum 
and femoral heads was consistently higher for IMRT and VMAT than for 
the 3DCRT treatments. The data in Table 3 suggests that the rectal dose 
sparing achievable with 3DCRT decreases with increasing CTV size; a 
trend not observed for the IMRT and VMAT modalities. The lowest 
observed femoral head doses were achieved using VMAT and the lowest 
rectal doses were achieved using IMRT. T-test results shown in Table 3 
indicate that the differences between these organ-at-risk doses are 
significant when 3DCRT is compared to either IMRT or VMAT (p<0.001 for 
rectums and femoral heads in most cases). 
 
The results of the dose assessments for IMRT and VMAT treatments 
involving the delivery of a 78 Gy PTV coverage prescription are presented 
in Table 4. A statistically significant difference in femoral head dose 
sparing (p<0.001 for median dose) can be observed. Table 3 suggests 
that any differences between IMRT and VMAT dose sparing, in terms of 
both rectal and femoral median dose values, is not statistically significant 
when like-sized CTVs are compared. Table 3 also suggests that there is no 
significant difference in conformity between IMRT and VMAT. 
 
The conformity scores for IMRT and VMAT listed in Table 1 are similar, 
with both modalities showing greater conformity than the 3DCRT 
treatments. Table 3 shows significant differences between 3DCRT and 
both IMRT and VMAT (p<0.001 for CN), when conformity indices and 
conformation numbers are evaluated. These results confirm that the high 
doses in the treatment plans are generally better matched to the target 
volumes, and provide better avoidance of healthy tissues, in the IMRT and 
VMAT treatment plans than in the 3DCRT plans. 
 
Discussion:  
The results of a retrospective dose assessment of a large number of 
treated radiotherapy plans (presented in Table 1), stratified for CTV size 
and PTV prescription (presented in Tables 3 and 4 respectively), support 
observations made in smaller, prospective and retrospective treatment 
plan quality studies. The observation that the intensity-modulated 
treatments provide improved organ-at-risk sparing with only slightly 
reduced PTV dose homogeneity compared with conventional 3DCRT 
treatments, for the 163 cases examined here, confirms observations 
made in previous nine-, ten- and twenty-patient planning studies.5,7,8 
 
The observation of improved organ-at-risk sparing with intensity-
modulated treatments complements Zelefsky et al.’s5 extensive 
comparison of the treatment outcomes achieved using IMRT with 3DCRT.  
Zelefsky et al.5 found that, in a large cohort of 3DCRT and IMRT patients, 
the risk of several rectal complications was significantly lower in the IMRT 
patients. 
 
The differences between organ-at-risk doses for the 3DCRT and intensity-
modulated plans examined in this study were sufficiently large that 
despite a 10% escalation in the mean prescribed dose to the PTV, 
compared to the 3DCRT treatments, the mean rectal volumes covered by 
doses of 40 Gy and 60 Gy were approximately halved in the intensity-
modulated treatments (see Table 1). The 3DCRT treatments, on average, 
failed to meet Hansen and Roach's22 recommendation that less than 50% 
of the rectum should receive a dose of 40 Gy. Almost all of the IMRT and 
VMAT treatments were able to meet this criterion.  
 
Based on the results shown in Tables 1-4, neither of the two intensity-
modulated treatment modalities appears preferable to the other. Smaller 
studies have shown that preferable organ at risk sparing can be provided 
by IMRT plans4 or by VMAT plans9,10,11 or by each of the two modalities for 
different organs at risk.14 Results shown in Tables 1 and 4 indicate that 
while the VMAT treatments appear to provide reduced rectal sparing and 
improved femoral sparing when all patient plans are examined together, 
the statistical significance of this result decreases when the patient plans 
are stratified by target size. This result provides confirmation of the value 
of delivering intensity-modulated treatments using VMAT at the centres 
involved in this study. For our patient treatments, VMAT provided dose 
distributions that were similar to IMRT (see Table 3) while using fewer 
monitor units (see Table 1) and requiring less beam-on time than IMRT. 
These results also provide confirmation of the value of performing 
detailed, stratified analyses on large patient data sets. 
 
The evaluation of 163 patient plans should be regarded as one of the 
strengths of our study design. The use of this large number of patient 
plans made it possible for data analysis to be stratified in terms of both 
target volume and prescription dose, to provide more detailed analysis of 
apparent trends in plan quality than had previously been available. 
Clearly, the investigation of such a large patient cohort made prospective 
re-planning of the treatments, using modalities other than those with 
which they were treated, clinically unachievable. Such prospective re-
planning is an obvious direction for future study. However, we expect that 
retrospective treatment plan auditing and quality assurance will be the 
major focus of future studies. It is likely that, as computational tools such 
as TADA18 become more available, automated retrospective analysis of 
ever larger numbers of treatment plans will become part of routine clinical 
practise.   
 
Conclusion:  
This retrospective dosimetric analysis of 163 clinically delivered 3DCRT, 
IMRT and VMAT radiotherapy treatment plans, delivered across 5 centres 
operated by one organisation, has demonstrated that although the PTV 
dose homogeneity achieved by the IMRT and VMAT plans was slightly 
reduced, these intensity-modulated radiotherapy techniques permitted an 
improvement in conformity and organ-at-risk sparing that makes them 
preferable for future treatments of prostate carcinomas. For the patient 
treatment cohort examined in this work, no statistically significant 
differences in dosimetric quality were observed between IMRT and VMAT 
across patients with like-sized CTVs. The value of using intensity-
modulated treatment modalities, such as IMRT and VMAT, is most 
apparent in their increased compliance with recommended organ-at-risk 
dose constraints, compared to conventional 3DCRT treatments, potentially 
leading to improved treatment outcomes. 
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Tables  
Table 1 - Summary of patient cohort information and dose metrics 
Values represent mean (± 1 standard deviation) over entire patient cohort for each modality. P-value (significance) calculated using two-
tailed Welch’s T-Test.  
†Normalized against patient prescription dose before averaging. ‡Normalized against patient median PTV dose before averaging. 
Averaged Parameter 3DCRT IMRT VMAT P3DCRT-IMRT P3DCRT-VMAT PIMRT-VMAT 
# of patients 83 33 47 - - - 
Gleason score 7.4 ± 0.8 7.4 ± 0.9 7.7 ± 1.0 0.705 0.049 0.238 
   Primary grade 3.6 ± 0.5 3.5 ± 0.5 3.6 ± 0.6 0.095 0.745 0.245 
   Secondary grade 3.6 ± 0.7 3.8 ± 0.8 4.0 ± 0.7 0.050 <0.001 0.428 
Clinical target volume (cc) 62 ± 23 52 ± 22 56 ± 20 0.065 0.185 0.487 
Prescription dose (Gy) 68 ± 3 78 ± 2 76 ± 3 <0.001 <0.001 0.001 
Monitor units (MU) 323 ± 28 976 ± 187 783 ± 144 <0.001 <0.001 <0.001 
MU efficiency (MU / Gy) 4.7 ± 0.4 12.6 ± 2.7 10.3 ± 2.0 <0.001 <0.001 <0.001 
Treatment volume       
Minimum dose† 0.95 ± 0.03 0.90 ± 0.10 0.95 ± 0.02 0.021 0.949 0.020 
D98% dose† 0.97 ± 0.02 0.96 ± 0.05 0.97 ± 0.02 0.150 0.805 0.185 
Median dose† 1.00 ± 0.01 1.01 ± 0.01 1.00 ± 0.02 0.286 0.867 0.354 
D2% dose† 1.02 ± 0.02 1.04 ± 0.01 1.03 ± 0.02 <0.001 0.025 0.152 
Maximum dose† 1.03 ± 0.02 1.06 ± 0.02 1.05 ± 0.02 <0.001 <0.001 0.685 
Homogeneity index 0.05 ± 0.02 0.08 ± 0.05 0.06 ± 0.01 0.003 <0.001 0.044 
Rectum       
Median dose‡ 0.65 ± 0.16 0.32 ± 0.08 0.40 ± 0.12 <0.001 <0.001 0.002 
V70Gy coverage (3 ± 7)% (11 ± 4)% (11 ± 6)% <0.001 <0.001 0.950 
V60Gy coverage (33 ± 12)% (16 ± 4)% (17 ± 8)% <0.001 <0.001 0.198 
V40Gy coverage (55 ± 15)% (28 ± 4)% (33 ± 14)% <0.001 <0.001 0.024 
Femoral Head       
Median dose‡ 0.58 ± 0.08 0.33 ± 0.09 0.28 ± 0.09 <0.001 <0.001 <0.001 
V50Gy coverage (1 ± 4)% (1 ± 1)% (0 ± 1)% 0.082 0.005 0.056 
Conformity indices       
RTOG conformity 1.67 ± 0.18 1.16 ± 0.14 1.21 ± 0.10 <0.001 <0.001 0.070 
van't Riet conformity 0.60 ± 0.06 0.82 ± 0.09 0.82 ± 0.05 <0.001 <0.001 0.838 
3DCRT, three-dimensional conformal radiation therapy; IMRT, intensity-modulated radiation therapy; VMAT, volumetric-modulated arc 
therapy; Dn%, dose received by n% of volume; Vn, percentage of volume receiving dose n; EUD, equivalent uniform dose; RTOG, 
Radiation Therapy Oncology Group.
Table 2 – Summary of adherence to OAR dose constraints 
Values represent the percentage of plans adhering to the OAR dose 
coverage constraints. 
Averaged Parameter 3DCRT IMRT VMAT 
Rectum    
V70Gy < 20% 95% 100% 91% 
V60Gy < 35% 56% 100% 96% 
V40Gy < 50% 27% 100% 87% 
Femoral Head    
V50Gy < 5% 90% 97% 98% 
OAR, organ-at-risk; 3DCRT, three-dimensional conformal radiation 
therapy; IMRT, intensity-modulated radiation therapy; VMAT, volumetric-
modulated arc therapy; Vn, percentage of volume receiving dose n. 
  
Table 3 - Summary of small, medium and large CTV cohort dose metrics 
Values represent mean (± 1 standard deviation) over each CTV size (small <50 cc, medium 50-70 cc, and large >70 cc) cohort for each 
modality. P-value (significance) calculated using two-tailed Welch’s T-Test. 
†Normalized against patient prescription dose before averaging. ‡Normalized against patient median PTV dose before averaging. 
Averaged Parameter 3DCRT IMRT VMAT P3D-IMRT P3D-VMAT PIMRT-VMAT 
# of patients       
small CTV cohort 23 14 13 - - - 
medium CTV cohort 16 7 16 - - - 
large CTV cohort 24 4 5 - - - 
Median PTV dose†       
small CTV cohort 0.99 ± 0.01 1.01 ± 0.01 1.01 ± 0.02 0.005 0.029 0.746 
medium CTV cohort 1.00 ± 0.01 1.00 ± 0.02 1.00 ± 0.02 0.765 0.282 0.357 
large CTV cohort 1.01 ± 0.01 1.00 ± 0.01 1.00 ± 0.03 0.127 0.975 0.583 
PTV homogeneity index       
small CTV cohort 0.04 ± 0.01 0.09 ± 0.08 0.07 ± 0.01 <0.001 0.042 0.308 
medium CTV cohort 0.05 ± 0.01 0.08 ± 0.01 0.06 ± 0.01 <0.001 0.002 0.034 
large CTV cohort 0.06 ± 0.04 0.07 ± 0.02 0.06 ± 0.01 0.590 0.733 0.407 
Median rectal dose‡       
small CTV cohort 0.57 ± 0.17 0.33 ± 0.10 0.40 ± 0.16 <0.001 0.005 0.184 
medium CTV cohort 0.73 ± 0.14 0.31 ± 0.09 0.43 ± 0.10 <0.001 <0.001 0.017 
large CTV cohort 0.73 ± 0.13 0.33 ± 0.07 0.45 ± 0.09 <0.001 <0.001 0.057 
Median femoral dose‡       
small CTV cohort 0.58 ± 0.06 0.32 ± 0.08 0.26 ± 0.07 <0.001 <0.001 0.006 
medium CTV cohort 0.57 ± 0.07 0.28 ± 0.14 0.31 ± 0.06 <0.001 <0.001 0.817 
large CTV cohort 0.60 ± 0.11 0.38 ± 0.03 0.34 ± 0.05 <0.001 <0.001 0.075 
RTOG conformity       
small CTV cohort 1.59 ± 0.13 1.17 ± 0.11 1.24 ± 0.12 <0.001 <0.001 0.122 
medium CTV cohort 1.69 ± 0.20 1.08 ± 0.22 1.18 ± 0.08 <0.001 <0.001 0.306 
large CTV cohort 1.72 ± 0.19 1.11 ± 0.04 1.19 ± 0.13 <0.001 <0.001 0.250 
van't Riet conformity       
small CTV cohort 0.63 ± 0.05 0.81 ± 0.11 0.80 ± 0.07 <0.001 <0.001 0.854 
medium CTV cohort 0.60 ± 0.06 0.82 ± 0.09 0.83 ± 0.04 <0.001 <0.001 0.720 
large CTV cohort 0.58 ± 0.07 0.90 ± 0.03 0.83 ± 0.07 <0.001 <0.001 0.082 
3DCRT, three-dimensional conformal radiation therapy; IMRT, intensity-modulated radiation therapy; VMAT, volumetric-modulated arc 
therapy; CTV, clinical target volume; PTV, planning target volume; RTOG, Radiation Therapy Oncology Group
 Table 4 - Summary of 78 Gy prescription cohort dose metrics 
Values represent mean (± 1 standard deviation) over 78 Gy prescription 
cohorts for each modality. P-values (significance) calculated using two-
tailed Welch’s T-Test. 
Averaged Parameter IMRT VMAT P 
# of patients 31 27 - 
Clinical target volume (cc) 52 ± 22 51 ± 19 0.690 
Monitor units (MU) 967 ± 172 768 ± 117 <0.001 
MU efficiency (MU / Gy) 12.4 ± 2.2 9.9 ± 1.5 <0.001 
Treatment volume    
Minimum dose (Gy) 71.7 ± 3.5 73.9 ± 0.7 0.002 
D98% dose (Gy) 75.1 ± 1.3 75.0 ± 1.2 0.662 
Median dose (Gy) 78.4 ± 0.8 77.6 ± 1.1 0.004 
D2% dose (Gy) 80.8 ± 1.1 79.7 ± 1.3 0.003 
Maximum dose (Gy) 82.4 ± 1.4 81.4 ± 1.3 0.005 
Homogeneity index 0.07 ± 0.02 0.06 ± 0.01 0.004 
Rectum    
Median dose (Gy) 24.9 ± 6.3 26.6 ± 7.9 0.390 
EUD (Gy) 59.0 ± 2.6 59.0 ± 3.5 0.956 
V70Gy coverage (11 ± 3)% (11 ± 5)% 0.995 
V60Gy coverage (16 ± 4)% (16 ± 6)% 0.709 
V40Gy coverage (28 ± 4)% (30 ± 11)% 0.351 
Femoral Head    
Median dose (Gy) 26.2 ± 7.1 20.9 ± 7.1 <0.001 
EUD (Gy) 30.7 ± 3.6 24.5 ± 6.8 <0.001 
V50Gy coverage (1 ± 1)% (0 ± 1)% 0.136 
Conformity indices    
RTOG conformity 1.16 ± 0.15 1.21 ± 0.08 0.115 
van't Riet conformity 0.83 ± 0.07 0.82 ± 0.04 0.418 
IMRT, intensity-modulated radiation therapy; VMAT, volumetric-
modulated arc therapy; D%, dose to percentage of volume; Vn, 
percentage of volume with dose; EUD, equivalent uniform dose; RTOG, 
Radiation Therapy Oncology Group. 
